Mary-EllenTaplinMD

Oncology • Boston, MA

Associate Professor of Medicine, Dana-Farber Cancer Institute

Join to view full profile

Dr. Taplin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Taplin's full profile

Already have an account?

Office
450 Brookline Ave
D1230
Boston, MA 02115
Phone+1 617-582-7221

Fax+1 617-632-2165
Is this information wrong?

Education & Training

Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 1990 - 1993
UMass Chan Medical SchoolResidency, Internal Medicine, 1986 - 1990
University of Massachusetts Medical SchoolClass of 1986

Certifications & Licensure

NH State Medical License 2023 - 2025
MA State Medical License 1987 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2009-2014
Boston Magazine Castle Connolly, 2008-2013
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy Start of enrollment: 1997 Jan 01
Completed
A Study of Docetaxel Plus Carboplatin in Patients With Hormone Refractory Prostate Cancer Start of enrollment: 2004 Jan 01
Completed
Phase 2
Mifepristone (RU-486) in Androgen Independent Prostate Cancer Start of enrollment: 2005 Feb 01
Completed
Phase 2
MRI-guided Bone Marrow Biopsies of Prostate Cancer Patients Start of enrollment: 2001 Jul 01
Completed
Not Applicable
Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment Start of enrollment: 2004 Mar 01
Completed
Phase 2
Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy Start of enrollment: 2006 Jun 01
Completed
Phase 2
RAD001 and Bicalutamide for Androgen Independent Prostate Cancer Start of enrollment: 2008 Feb 01
Completed
Phase 2
Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer Start of enrollment: 2008 Jun 01
Completed
Phase 2
Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy Start of enrollment: 2008 Oct 01
Completed
Phase 2
ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer Start of enrollment: 2009 Oct 01
Completed
Phase 1
Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy Start of enrollment: 2011 Jan 01
Completed
Phase 2
Biomarkers in Bone Marrow and Blood Samples From Patients With Prostate Cancer Treated With Ketoconazole Start of enrollment: 2010 Dec 01
Withdrawn
Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer Start of enrollment: 2011 Jul 01
Completed
Phase 1, Phase 2
Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer Start of enrollment: 2011 Sep 01
Completed
Phase 2
A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer Start of enrollment: 2012 Dec 01
Terminated
Phase 2
Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer Start of enrollment: 2013 Sep 13
Completed
Phase 2
Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer Start of enrollment: 2014 Jan 27
Active, not recruiting
Phase 2
A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer Start of enrollment: 2014 Jun 01
Completed
Phase 2
Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone. Start of enrollment: 2015 May 01
Completed
Phase 2
Personal Web Page In Clinical Trial Participant Education Start of enrollment: 2014 Jul 21
Completed
Not Applicable
Join now to see all

Publications & Presentations

PubMed

Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer.
Atish D Choudhury, Lucia Kwak, Alexander Cheung, Kathryn M Allaire, Jaqueline Marquez, David D Yang, Abhishek Tripathi, Jacqueline M Kilar, Meredith Flynn, Brianna May...> ;Cancer Immunology Research. 2024 Mar 29
PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (A...
Rahul Aggarwal, Glenn Heller, David W Hillman, Han Xiao, Joel Picus, Mary-Ellen Taplin, Tanya Dorff, Leonard Appleman, Douglas Weckstein, Akash Patnaik, Alan Bryce, Da...> ;Journal of Clinical Oncology. 2024 Apr 1
Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial.
Lalji, A., Mark C Markowski, Mary-Ellen Taplin, Rahul Aggarwal, Laura A Sena, Hao Wang, Hanfei Qi, Aliya Lalji, Victoria Sinibaldi, Michael A Carducci, Channing J Pall...> ;Nature Communications. 2024 Jan 2
1 citations
Postradical prostatectomy prostate-specific antigen outcomes after 6 versus 18 months of perioperative androgen-deprivation therapy in men with localized, unfavorable ...
Rana R McKay, Wanling Xie, Xiaoyu Yang, Andres Acosta, Dana Rathkopf, Vincent P Laudone, Glenn J Bubley, David J Einstein, Peter Chang, Andrew A Wagner, Christopher J ...> ;Cancer. 2024 May 1
5 citations
Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker.
Taylor, M., Wu, C., Fridy, P., Zhang, S., Senussi, Y., Wolters, J., Cajuso, T., Cheng, W., Heaps, J., Miller, B., Mori, K., Cohen, L., Jiang, H., Molloy, K., Chait, B....> ;Cancer Discovery. 2023 Dec 12
Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.
Orme, J., Taza, F., De Sarkar, N., Tewari, A., Arsalan Naqvi, S., Riaz, I., Childs, D., Omar, N., Adra, N., Ashkar, R., Cheng, H., Schweizer, M., Sokolova, A., Agarwal...> ;European Urology Oncology. 2023 Dec 9
Adjuvant and salvage radiotherapy after neoadjuvant therapy and radical prostatectomy for high-risk localized prostate cancer.
Praful Ravi, Lucia Kwak, Wout Devlies, Wanling Xie, Fallon Chipidza, Xiaoyu Yang, Glenn Bubley, Irving Kaplan, Adam S Kibel, Paul Nguyen, Mary-Ellen Taplin> ;The Prostate. 2024 Mar 1
Pretest Video Education Versus Genetic Counseling for Patients With Prostate Cancer: ProGen, A Multisite Randomized Controlled Trial.
Huma Q Rana, Jill E Stopfer, Michelle Weitz, Lindsay Kipnis, Diane R Koeller, Samantha Culver, Joanna Mercado, Rebecca Sue Gelman, Meghan Underhill-Blazey, Bradley A M...> ;JCO Oncology Practice. 2023 Nov 1
2 citations
Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial.
Takayuki Sumiyoshi, Xiaofei Wang, Evan W Warner, Andrea Sboner, Matti Annala, Michael Sigouros, Kevin Beja, Kei Mizuno, Shengyu Ku, Ladan Fazli, James Eastham, Mary-El...> ;Journal of the National Cancer Institute. 2024 Jan 10
3 citations
SNMMI Consensus Statement on Patient Selection and Appropriate Use ofLu-PSMA-617 Radionuclide Therapy.
Thomas A Hope, Emmanuel S Antonarakis, Lisa Bodei, Jeremie Calais, Amir Iravani, Heather Jacene, Phillip J Koo, Alicia K Morgans, Joseph R Osborne, Scott T Tagawa, Mar...> ;Journal of Nuclear Medicine. 2023 Sep 1
24 citations
Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conferenc...
Sharifi, N., Silke Gillessen, Alberto Bossi, Ian D Davis, Johann de Bono, Karim Fizazi, Nicholas D James, Nicolas Mottet, Neal Shore, Eric Small, Matthew Smith, Christ...> ;European Journal of Cancer. 2023 May 1
3 citations
Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial).
Michael J Morris, Glenn Heller, David W Hillman, Olivia Bobek, Charles Ryan, Emmanuel S Antonarakis, Alan H Bryce, Olwen Hahn, Himisha Beltran, Andrew J Armstrong, Law...> ;Journal of Clinical Oncology. 2023 Jun 20
5 citations
Clinical Implementation ofLu-PSMA-617 in the United States: Lessons Learned and Ongoing Challenges.
Praful Ravi, Bridget Whelpley, Emma Kelly, Andrew Wolanski, Jolivette Ritzer, Matthew Robertson, Hina Shah, Alicia K Morgans, Xiao X Wei, Rajitha Sunkara, Mark Pomeran...> ;Journal of Nuclear Medicine. 2023 Mar 1
1 citations
Gaining metabolic insight in older men undergoing androgen deprivation therapy for prostate cancer (the ADT & Metabolism Study): Protocol of a longitudinal, observatio...
Milena Braga-Basaria, Thomas G Travison, Mary-Ellen Taplin, Alexander Lin, Alyssa B Dufour, Daniel Habtemariam, Paul L Nguyen, Adam S Kibel, Praful Ravi, Richelle Bear...> ;Plos One. 2023 Jan 1
33 citations
Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal T...
Silke Gillessen, Alberto Bossi, Ian D Davis, Johann de Bono, Karim Fizazi, Nicholas D James, Nicolas Mottet, Neal Shore, Eric Small, Mathew Smith, Christopher Sweeney,...> ;European Urology. 2023 Mar 1
3 citations
Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer.
Christopher T Su, Emily Nizialek, Jacob E Berchuck, Panagiotis J Vlachostergios, Ryan Ashkar, Alexandra Sokolova, Pedro C Barata, Rahul R Aggarwal, Rana R McKay, Neera...> ;The Prostate. 2023 Feb 1
6 citations
A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer.
Shuang G Zhao, Jamie M Sperger, Jennifer L Schehr, Rana R McKay, Hamid Emamekhoo, Anupama Singh, Zachery D Schultz, Rory M Bade, Charlotte N Stahlfeld, Cole S Gilsdorf...> ;The Journal of Clinical Investigation. 2022 Nov 1
14 citations
Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984.
Joseph W Kim, Rana R McKay, Marc R Radke, Shilin Zhao, Mary-Ellen Taplin, Nancy B Davis, Paul Monk, Leonard J Appleman, Primo N Lara Jr, Ulka N Vaishampayan, Jingsong ...> ;Journal of Clinical Oncology. 2023 Feb 1
13 citations
Neoadjuvant Novel Hormonal Therapy Followed by Prostatectomy versus Up-Front Prostatectomy for High-Risk Prostate Cancer: A Comparative Analysis.
Praful Ravi, Lucia Kwak, Wanling Xie, Kaitlin Kelleher, Andres M Acosta, Rana R McKay, Adam S Kibel, Mary-Ellen Taplin> ;The Journal of Urology. 2022 Oct 1
3 citations
Patterns of structural variation define prostate cancer across disease states.
Meng Zhou, Minjeong Ko, Anna Ch Hoge, Kelsey Luu, Yuzhen Liu, Magdalena L Russell, William W Hannon, Zhenwei Zhang, Jian Carrot-Zhang, Rameen Beroukhim, Eliezer M Van ...> ;JCI Insight. 2022 Sep 8
3 citations
Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate Cancer.
Jacob E Berchuck, Daniel Boiarsky, Rebecca Silver, Rajitha Sunkara, Heather M McClure, Harrison K Tsai, Stephanie Siegmund, Alok K Tewari, Jonathan A Nowak, Neal I Lin...> ;JCO Precision Oncology. 2022 Aug 1
4 citations
What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021.
Fabio Turco, Andrew Armstrong, Gerhardt Attard, Tomasz M Beer, Himisha Beltran, Anders Bjartell, Alberto Bossi, Alberto Briganti, Rob G Bristow, Muhammad Bulbul, Orazi...> ;European Urology. 2022 Jul 1
55 citations
Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021.
Silke Gillessen, Andrew Armstrong, Gert Attard, Tomasz M Beer, Himisha Beltran, Anders Bjartell, Alberto Bossi, Alberto Briganti, Robert G Bristow, Muhammad Bulbul, Or...> ;European Urology. 2022 Jul 1
13 citations
Genetic testing in prostate cancer management: Considerations informing primary care.
Veda N Giri, Todd M Morgan, David S Morris, Jacob E Berchuck, Colette Hyatt, Mary-Ellen Taplin> ;CA. 2022 Jul 1
Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [...
Fabio Turco, Andrew Armstrong, Gerhardt Attard, Tomasz M Beer, Himisha Beltran, Anders Bjartell, Alberto Bossi, Alberto Briganti, Rob G Bristow, Muhammad Bulbul, Orazi...> ;European Urology. 2022 Jul 1
Join now to see all

Lectures

PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to ...
2019 ASCO Annual Meeting - 6/1/2019
Optimizing Androgen Receptor Targeting Strategies Perspective
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Other

Clinical presentation and diagnosis of prostate cancer
Taplin M, Smith JA, Kantoff PW
http://www.uptodate.com/contents/clinical-presentation-and-diagnosis-of-prostate-cancer
UpToDate, Wolters Kluwer Health - 2013-02-05
Initial staging and evaluation of men with newly diagnosed prostate cancer
Taplin M, Smith JA, Kantoff PW
http://www.uptodate.com/contents/initial-staging-and-evaluation-of-men-with-newly-diagnosed-prostate
UpToDate, Wolters Kluwer Health - 2013-02-05
Testicular sex cord stromal tumors
Taplin M
http://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors
UpToDate, Wolters Kluwer Health - 2012-04-18

Authored Content

Clinical and Genomic Characterization of Low–Prostate-Specific Antigen, High-Grade Prostate CancerFebruary 2018

Press Mentions

Neoadjuvant NHAs Followed by Surgery Can Improve Key Outcomes in High-Risk Prostate Cancer PatientsSeptember 12th, 2022
The Prostate Cancer Foundation Announces First Ever Pcf-Pfizer Global Health Equity Challenge Award WinnersApril 29th, 2022
Rana R. McKay, MD: Developing Clinical Trials to Answer Questions Raised in PracticeApril 20th, 2022
Join now to see all